Zydus announced filing submission in US for saroglitazar (PPAR α/γ agonist) in 2L PBC (PDUFA date of November 27, 2026)
Zydus announced it has filed its US NDA for saroglitazar (PPAR α/γ agonist) in 2L PBC and has announced that the FDA has accepted its NDA for saroglitazar (PPAR α/γ agonist) for the treatment of 2L PBC with Priority Review, with a PDUFA date of November 27, 2026.
- Zydus plans to launch saroglitazar in the US on its own, with commercialization strategy in preparation, through team hiring, and pre-launch activities
- Following favorable approval in the US, Zydus will assess co-partnering or licensing strategies for EU and other market launches
- Zydus maintains a key commercial goal of increasing in its US commercial footprint through growth of its specialty pharmaceutical business driven by the planned launch of saroglitazar, the proposed acquisition of Assertio Holdings, specialized in oncology supportive care therapy, and its biosimilar initiatives
- Management highlighted upcoming full data readout from the Ph2b/3 EPICS-III trial (N=196; PCD: Apr 2025) at EASL 2026 (LBO-001)
CI assessment:
- While Zydus’ US NDA filing is broadly aligned with previous guidance of Q1 2026, the company remains vague regarding exact launch timelines, which depend on the upcoming FDA decision to formally accept the NDA
- Two potential scenarios remain, representing a slight delay from previous projections; if saroglitazar is granted fast track review (~6-9 mos from acceptance), approval could be expected as early Q1 2027 (compared to prior assumptions Q3 2026)
- For a standard review (~12 mos from acceptance), approval would be estimated for Q2 2027 (compared to prior assumptions Q1 2027)
- If approved in the US, saroglitazar would become the third PPAR agonist available in 2L PBC, joining Ipsen’s Iqirvo and Gilead’s Livdelzi, both approved in 2024
- For the first time, Zydus mentioned explicit plans for an ex-US saroglitazar launch, signaling openness to potential commercial partners in the EU and other markets
-
While early data suggests a comparable profile to existing PPAR agonists approved in PBC, Zydus’ upcoming presentation of the full data from the Phase 2b/3 EPICS-III trial at EASL will provide additional context on the saroglitazar’s competitive positioning
-
An absolute biochemical response rate of 56.7% would be numerically comparable to Iqirvo (51%) and Livdelzi (61.7%), though cross-trial comparisons are limited by differences in baseline characteristics
-
ALP normalization rate of 8.2% lags behind Iqirvo (15%) and Livdelzi (25%), and may impact HCP perceptions of Saroglitazar’s profile
-
Saroglitazar's dual PPARα/γ mechanism differentiates from Iqirvo (PPARα/δ) and Livdelzi (PPARδ); PPARγ driven insulin sensitization may offer a unique niche for PBC patients with MASH
-
US commercial infrastructure remains limited at approximately 18–20 people; a field sales force of 60–70 personnel is planned, with senior leadership hiring underway (Primary, May 2025) consistent with April 2026 job postings reflecting a transition from clinical operations toward commercial build-out
-
Zydus has been expanding its US footprint through M&A, including the Agenus acquisition and launch of Zylidac Bio LLC (Jan 2026); the proposed Ardelyx acquisition ($2.5B, unconfirmed) would add a GI commercial presence, though management has dismissed near-term specialty acquisitions to synergize with the saroglitazar launch
-
Zydus also launched a dedicated PBC awareness website (PBC Warning Sign) in early May 2026, covering ALP as an early indicator of cholestatic activity, disease trajectories, and guideline-aligned monitoring recommendations, signaling early-stage disease education infrastructure building ahead of a potential launch
-
Zydus’s Q4 FY2025 earnings call commentary and Primary Intelligence (May 2026) indicate a US-first strategy for saroglitazar, with the company planning to self-launch in PBC using existing infrastructure while delaying EMA filing until at least 2028 due to limited cash flow and on-ground resources